Skip to navigation Skip to content
  • Woodruff
  • Business
  • Health Sciences
  • Law
  • Rose
  • Oxford College
  • Theology
  • Schools
    • Undergraduate

      • Emory College
      • Oxford College
      • Business School
      • School of Nursing

      Community

      • Emory College
      • Oxford College
      • Business School
      • School of Nursing
    • Graduate

      • Business School
      • Graduate School
      • School of Law
      • School of Medicine
      • School of Nursing
      • School of Public Health
      • School of Theology
  • Libraries
    • Libraries

      • Robert W. Woodruff
      • Business
      • Chemistry
      • Health Sciences
      • Law
      • MARBL
      • Music & Media
      • Oxford College
      • Theology
    • Library Tools

      • Course Reserves
      • Databases
      • Digital Scholarship (ECDS)
      • discoverE
      • eJournals
      • Electronic Dissertations
      • EmoryFindingAids
      • EUCLID
      • ILLiad
      • OpenEmory
      • Research Guides
  • Resources
    • Resources

      • Administrative Offices
      • Emory Healthcare
      • Academic Calendars
      • Bookstore
      • Campus Maps
      • Shuttles and Parking
      • Athletics: Emory Eagles
      • Arts at Emory
      • Michael C. Carlos Museum
      • Emory News Center
      • Emory Report
    • Resources

      • Emergency Contacts
      • Information Technology (IT)
      • Outlook Web Access
      • Office 365
      • Blackboard
      • OPUS
      • PeopleSoft Financials: Compass
      • Careers
      • Human Resources
      • Emory Alumni Association
  • Browse
    • Works by Author
    • Works by Journal
    • Works by Subject
  • For Authors
    • How to Submit
    • Deposit Advice
    • Deposit Instructions
    • Author Rights
    • FAQ
    • Emory Open Access Policy
    • Open Access Fund
  • About OpenEmory
    • About OpenEmory
    • About Us
    • Citing Articles
    • Contact Us
    • Privacy Policy
    • Terms of Use
 
Contact Us

Filter Results:

Year

  • 2012 (19)
  • 2016 (14)
  • 2017 (14)
  • 2013 (11)
  • 2020 (10)
  • 2010 (8)
  • 2019 (7)
  • 2014 (6)
  • 2011 (5)
  • 2015 (5)
  • 2018 (5)
  • 2021 (4)
  • 2007 (3)
  • 2022 (3)
  • 2009 (2)
  • 2023 (2)
  • 1997 (1)
  • 1999 (1)
  • 2000 (1)
  • 2006 (1)

Author

  • Tansey, Malu (30)
  • Tansey, MariadeLourdes (25)
  • Chen, Guangping (20)
  • Chang, Jianjun (13)
  • Eaton, Douglas C (13)
  • Bao, Hui-Fang (12)
  • Pinter, Martin (11)
  • Chung, Jaegwon (8)
  • Yu, Ling (7)
  • Chen, Xi (6)
  • Houser, Madelyn (6)
  • Joers, Valerie (6)
  • Alli, Abdel A. (5)
  • Barnum, Christopher J. (5)
  • Liu, Bing-Chen (5)
  • Lu, Xiao-Yu (5)
  • Ma, Heping (5)
  • Sands, Jeff M (5)
  • Song, Xiang (5)
  • Thai, Tiffany (5)
  • Yang, Baoxue (5)
  • Al-Khalili, Otor (4)
  • Alli, Abdel (4)
  • Bichler, Edyta K. (4)
  • Blanchfield, Jennifer (4)
  • Cai, Hui (4)
  • Eaton, Douglas (4)
  • Frohlich, Otto (4)
  • Houser, Madelyn C. (4)
  • Jain, Lucky (4)
  • Kannarkat, George T. (4)
  • Ma, He-Ping (4)
  • Seburn, Kevin L. (4)
  • Song, John Z. (4)
  • Betarbet, Ranjita (3)
  • Carrasco, Dario (3)
  • Carter, Conner B. (3)
  • Duke, Billie Jeanne (3)
  • Duong, Duc (3)
  • Eidson, Lori N (3)
  • Evavold, Brian (3)
  • Factor, Stewart (3)
  • Klein, Janet (3)
  • Klein, Janet D (3)
  • Kukar, Thomas (3)
  • Kumar, Amrita (3)
  • Lah, James J (3)
  • Lee, Jae Kyung (3)
  • Lee, Jae-Kyung (3)
  • Levey, Allan I (3)
  • Li, Xuechen (3)
  • Neigh, Gretchen (3)
  • Nusrat, Asma (3)
  • Rangaraju, Srikant (3)
  • Rodrigues, Maria Elizabeth (3)
  • Sands, Jeff (3)
  • Su, Hua (3)
  • Trevino, Isaac (3)
  • Wang, Xueyong (3)
  • Yang, Li-Li (3)
  • Yang, Yuan (3)
  • Zhai, Yujia (3)
  • Alli, Alia A. (2)
  • Auvinen, Petri (2)
  • Balice-Gordon, Rita J. (2)
  • Bao, Qing (2)
  • Barnum, Christopher (2)
  • Barth, Olivia L. (2)
  • Bekhbat, Mandakh (2)
  • Boss, Jeremy (2)
  • Boulis, Nicholas (2)
  • Butkovich, Laura M. (2)
  • Carrasco, Dario I. (2)
  • Chandrasekharan, Bindu (2)
  • Chang, Qiang (2)
  • Choi, Inyeong (2)
  • Chokhawala, Harshal A. (2)
  • Collier, Timothy J. (2)
  • Cope, Timothy (2)
  • Cummings, Richard D. (2)
  • Dammer, Eric (2)
  • Deng, Qiudong (2)
  • Druey, Kirk M. (2)
  • Duffy, Megan F. (2)
  • Eaton, Amity F. (2)
  • El-Agnaf, Omar M. A. (2)
  • Feng, Xiuyan (2)
  • Fischer, Luke D. (2)
  • Gearing, Marla (2)
  • Geng, Xiaoqiang (2)
  • Glass, Jonathan D (2)
  • Hansen, Jason (2)
  • He, Jinzhao (2)
  • Helms, My N. (2)
  • Herrick, Mary K (2)
  • Hertzberg, Vicki (2)
  • Hertzberg, Vicki S (2)
  • Howe, Jacob W. (2)
  • Huang, Haidong (2)
  • Jones, Dean P (2)

Subject

  • Biology, Neuroscience (48)
  • Biology, Physiology (48)
  • Health Sciences, General (18)
  • Biology, Cell (16)
  • Health Sciences, Medicine and Surgery (16)
  • Health Sciences, Immunology (10)
  • Chemistry, Biochemistry (9)
  • Health Sciences, Pharmacology (9)
  • Biology, Microbiology (8)
  • Health Sciences, Pathology (8)
  • Biology, Animal Physiology (7)
  • Health Sciences, Oncology (7)
  • Biology, Genetics (5)
  • Biology, Molecular (3)
  • Engineering, Biomedical (3)
  • Health Sciences, Nursing (3)
  • Health Sciences, Public Health (3)
  • Health Sciences, Radiology (3)
  • Psychology, Behavioral (3)
  • Psychology, Cognitive (3)
  • Biology, Virology (2)
  • Chemistry, Pharmaceutical (2)
  • Health Sciences, Mental Health (2)
  • Health Sciences, Nutrition (2)
  • Health Sciences, Toxicology (2)
  • Psychology, Physiological (2)
  • Biology, Biostatistics (1)
  • Biology, General (1)
  • Computer Science (1)
  • Engineering, Environmental (1)
  • Health Sciences, Epidemiology (1)
  • Health Sciences, Pharmacy (1)
  • Psychology, Clinical (1)

Journal

  • Journal of Neuroscience Nursing (9)
  • Journal of Neuroinflammation (7)
  • Journal of Biological Chemistry (6)
  • PLoS ONE (6)
  • American Journal of Physiology - Renal Physiology (4)
  • Frontiers in Physiology (4)
  • npj Parkinson's Disease (4)
  • Experimental Neurology (3)
  • Frontiers in Immunology (3)
  • Neurobiology of Disease (3)
  • AJP - Renal Physiology (2)
  • American Journal of Physiology - Cell Physiology (2)
  • American Journal of Physiology - Lung Cellular and Molecular Physiology (2)
  • Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids (2)
  • FASEB Journal (2)
  • JOURNAL OF NEUROSCIENCE (2)
  • Journal of Parkinson's Disease (2)
  • Molecular Neurodegeneration (2)
  • Movement Disorders (2)
  • Neuroscience Letters (2)
  • Physiological Reports (2)
  • AJP - Lung Cellular and Molecular Physiology (1)
  • ALZHEIMERS RESEARCH & THERAPY (1)
  • ASN NEURO (1)
  • Acta Pharmaceutica Sinica B. (1)
  • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (1)
  • BBA - Molecular Cell Research (1)
  • BRAIN BEHAVIOR AND IMMUNITY (1)
  • Behavioural Brain Research (1)
  • Biochemical Journal (1)
  • Brain, Behavior, and Immunity (1)
  • CELLS (1)
  • Clinical and Translational Oncology (1)
  • Diagnostic Pathology (1)
  • EMBO Journal (1)
  • EUROPEAN JOURNAL OF NEUROSCIENCE (1)
  • FRONTIERS IN CELLULAR NEUROSCIENCE (1)
  • Frontiers in Neuroscience (1)
  • Frontiers in Pharmacology (1)
  • GASTROENTEROLOGY (1)
  • Glia (1)
  • Hypertension (1)
  • Inflammatory Bowel Diseases (1)
  • JOURNAL OF BIOLOGICAL CHEMISTRY (1)
  • Journal of Epithelial Biology & Pharmacology (1)
  • Journal of Neurochemistry (1)
  • Journal of Neuroimmune Pharmacology (1)
  • Journal of Neuroscience (1)
  • Journal of Physiology (1)
  • Journal of Proteome Research (1)
  • Journal of Virological Methods (1)
  • Journal of the American Society of Nephrology (1)
  • MOLECULAR NEURODEGENERATION (1)
  • MOVEMENT DISORDERS (1)
  • Molecular Psychiatry (1)
  • Molecular Therapy (1)
  • NATURE REVIEWS IMMUNOLOGY (1)
  • NEUROBIOLOGY OF DISEASE (1)
  • NEURON (1)
  • Oncotarget (1)
  • Pflügers Archiv European Journal of Physiology (1)
  • Pharmacology Research & Perspectives (1)
  • Physiological Genomics (1)
  • Proceedings of the American Thoracic Society (1)
  • Proceedings of the National Academy of Sciences (1)
  • Proceedings of the National Academy of Sciences of the United States of America (1)
  • Progress in Neurobiology (1)
  • SCIENTIFIC REPORTS (1)
  • Scientific Reports (1)
  • Thoracic Cancer (1)
  • Trials (1)
  • Vascular Cell (1)

Keyword

  • scienc (61)
  • technolog (61)
  • life (57)
  • biomedicin (56)
  • neurolog (35)
  • neurosci (35)
  • diseas (29)
  • cell (28)
  • activ (20)
  • protein (20)
  • alpha (19)
  • factor (19)
  • parkinson (19)
  • receptor (18)
  • inflamm (17)
  • neuroinflamm (16)
  • transport (16)
  • microglia (15)
  • neuron (15)
  • 2 (14)
  • channel (14)
  • express (14)
  • 1 (12)
  • b (12)
  • c (12)
  • necrosi (12)
  • neurodegener (12)
  • dopaminerg (11)
  • mice (11)
  • model (11)
  • molecular (11)
  • tnf (11)
  • urea (11)
  • a (10)
  • biolog (10)
  • immunolog (10)
  • rat (10)
  • brain (9)
  • gene (9)
  • kinas (9)
  • membran (9)
  • mous (9)
  • system (9)
  • 3 (8)
  • blood (8)
  • drug (8)
  • fluid (8)
  • immun (8)
  • in (8)
  • motor (8)
  • nigra (8)
  • oxid (8)
  • sclerosi (8)
  • stress (8)
  • substantia (8)
  • synuclein (8)
  • tumor (8)
  • associ (7)
  • biochemistri (7)
  • concentr (7)
  • ena (7)
  • enac (7)
  • nerv (7)
  • nervous (7)
  • t (7)
  • tcell (7)
  • alzheim (6)
  • cancer (6)
  • cerebrospin (6)
  • cerebrospinalfluid (6)
  • dopaminergicneuron (6)
  • epitheli (6)
  • gut (6)
  • injuri (6)
  • intracellular (6)
  • invivo (6)
  • microbiota (6)
  • neuromuscular (6)
  • phosphoryl (6)
  • sodium (6)
  • termin (6)
  • tnfalpha (6)
  • topic (6)
  • traffick (6)
  • vivo (6)
  • amyotroph (5)
  • apoptosi (5)
  • biomark (5)
  • calcium (5)
  • central (5)
  • clinic (5)
  • encephalomyel (5)
  • experiment (5)
  • growth (5)
  • human (5)
  • intestin (5)
  • junction (5)
  • later (5)
  • metabol (5)
  • multidisciplinari (5)

Author affiliation

  • Position object (104) (3)
  • Position object (78) (1)
  • Position object (83) (1)

Author department

  • Medicine: Nephrology (25)
  • Cell Biology: Admin (19)
  • Academic Advancement (10)
  • Biochem: Admin (7)
  • Pathology: Admin (7)
  • Pharmacology: Admin (6)
  • Psych: Admin (6)
  • Neurology: Cog Neurobehav (5)
  • Neurology: Movement Disor (5)
  • Core Labs (4)
  • Medicine: Pulmonary (4)
  • Micro/Immun: Admin (4)
  • Environmental Health (3)
  • Neurology: Neuromuscular (3)
  • Neurology: Stroke (3)
  • Peds: Neonatology (3)
  • Anesthesiology: Admin (2)
  • GDBBS (2)
  • Hum Gen: Admin (2)
  • Medicine: Digestive Dis (2)
  • Neurosurgery: Admin (2)
  • Peds: Gastroenterology (2)
  • Peds: Pulmonology (2)
  • Psych: Adult (2)
  • Rehab: Admin (2)
  • Urology: Admin (2)
  • BME: Admin (1)
  • BMI: Admin (1)
  • Chemistry (1)
  • Dermatology: Admin (1)
  • Dev & Cog Neuroscience (1)
  • Emerg Med: Admin (1)
  • Emory Temporary Services (1)
  • HMO: BMT (1)
  • Imaging Core (1)
  • Medicine: Admin (1)
  • Medicine: Cardiology (1)
  • Medicine: Endocrinology (1)
  • Medicine: Geriatrics (1)
  • Neurology: CND (1)
  • Neurology: Neuro-Rehab (1)
  • Peds: Children's Hrt Ctr (1)
  • Peds: Neuro & Neuropsych (1)
  • Rad Onc: Admin (1)
  • Rad: Admin (1)
  • Rad: Radiopharm Disc Lab (1)

Search Results for all work with filters:

  • Physiology: Admin

Work 1-10 of 122

Sorted by relevance
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. ...
>

Article

LRRK2 levels in immune cells are increased in Parkinson’s disease

by D.A Cook; G.T Kannarkat; A.F Cintron; Laura M. Butkovich; Kyle B. Fraser; J. Chang; N. Grigoryan; S.A Factor; Andrew B. West; J.M Boss; MariadeLourdes Tansey

2017

Subjects
  • Health Sciences, Medicine and Surgery
  • Health Sciences, Immunology
  • File Download
  • View Abstract

Abstract:Close

Mutations associated with leucine-rich repeat kinase 2 are the most common known cause of Parkinson’s disease. The known expression of leucine-rich repeat kinase 2 in immune cells and its negative regulatory function of nuclear factor of activated T cells implicates leucine-rich repeat kinase 2 in the development of the inflammatory environment characteristic of Parkinson’s disease. The aim of this study was to determine the expression pattern of leucine-rich repeat kinase 2 in immune cell subsets and correlate it with the immunophenotype of cells from Parkinson’s disease and healthy subjects. For immunophenotyping, blood cells from 40 Parkinson’s disease patients and 32 age and environment matched-healthy control subjects were analyzed by flow cytometry. Multiplexed immunoassays were used to measure cytokine output of stimulated cells. Leucine-rich repeat kinase 2 expression was increased in B cells (p = 0.0095), T cells (p = 0.029), and CD16+ monocytes (p = 0.01) of Parkinson’s disease patients compared to healthy controls. Leucine-rich repeat kinase 2 induction was also increased in monocytes and dividing T cells in Parkinson’s disease patients compared to healthy controls. In addition, Parkinson’s disease patient monocytes secreted more inflammatory cytokines compared to healthy control, and cytokine expression positively correlated with leucine-rich repeat kinase 2 expression in T cells from Parkinson’s disease but not healthy controls. Finally, the regulatory surface protein that limits T-cell activation signals, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), was decreased in Parkinson’s disease compared to HC in T cells (p = 0.029). In sum, these findings suggest that leucine-rich repeat kinase 2 has a regulatory role in immune cells and Parkinson’s disease. Functionally, the positive correlations between leucine-rich repeat kinase 2 expression levels in T-cell subsets, cytokine expression and secretion, and T-cell activation states suggest that targeting leucine-rich repeat kinase 2 with therapeutic interventions could have direct effects on immune cell function.

Article

SLC14A1: a novel target for human urothelial cancer

by R. Hou; X. Kong; B. Yang; Y. Xie; Guangping Chen

2017

Subjects
  • Health Sciences, Pharmacology
  • Health Sciences, General
  • File Download
  • View Abstract

Abstract:Close

Urinary bladder cancer is the second commonly diagnosed genitourinary malignancy. Previously, bio-molecular alterations have been observed within certain locations such as chromosome 9, retinoblastoma gene and fibroblast growth factor receptor-3. Solute carrier family 14 member 1 (SLC14A1) gene encodes the type-B urea transporter (UT-B) which facilitates the passive movement of urea across cell membrane, and has recently been related with human malignancies, especially for bladder cancer. Herein, we discussed the SLC14A1 gene and UT-B protein properties, aiming to elucidate the expression behavior of SLC14A1 in human bladder cancer. Furthermore, by reviewing some well-established theories regarding the carcinogenesis of bladder cancer, including several genome wide association researches, we have bridged the mechanisms of cancer development with the aberrant expression of SLC14A1. In conclusion, the altered expression of SLC14A1 gene in human urothelial cancer may implicate its significance as a novel target for research.

Article

DNA-based nanoparticle tension sensors reveal that T-cell receptors transmit defined pN forces to their antigens for enhanced fidelity

by Yang Liu; Jennifer Blanchfield; Victor Pui-Yan Ma; Rakieb Andargachew; Kornelia Galior; Zheng Liu; Brian Evavold; Khalid Salaita

2016

Subjects
  • Health Sciences, Immunology
  • File Download
  • View Abstract

Abstract:Close

T cells are triggered when the T-cell receptor (TCR) encounters its antigenic ligand, the peptide-major histocompatibility complex (pMHC), on the surface of antigen presenting cells (APCs). Because T cells are highly migratory and antigen recognition occurs at an intermembrane junction where the T cell physically contacts the APC, there are long-standing questions of whether T cells transmit defined forces to their TCR complex and whether chemomechanical coupling influences immune function. Here we develop DNA-based gold nanoparticle tension sensors to provide, to our knowledge, the first pN tension maps of individual TCR-pMHC complexes during T-cell activation. We show that naïve T cells harness cytoskeletal coupling to transmit 12-19 pN of force to their TCRs within seconds of ligand binding and preceding initial calcium signaling. CD8 coreceptor binding and lymphocyte-specific kinase signaling are required for antigenmediated cell spreading and force generation. Lymphocyte functionassociated antigen 1 (LFA-1) mediated adhesion modulates TCR-pMHC tension by intensifying its magnitude to values >19 pN and spatially reorganizes the location of TCR forces to the kinapse, the zone located at the trailing edge of migrating T cells, thus demonstrating chemomechanical crosstalk between TCR and LFA-1 receptor signaling. Finally, T cells display a dampened and poorly specific response to antigen agonists when TCR forces are chemically abolished or physically "filtered" to a level below ∼12 pN using mechanically labile DNA tethers. Therefore, we conclude that T cells tune TCR mechanics with pN resolution to create a checkpoint of agonist quality necessary for specific immune response.

Article

A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation

by Srikant Rangaraju; Syed Raza; Andrea Pennati; Qiudong Deng; Eric Dammer; Duc Duong; Michael W. Pennington; MariadeLourdes Tansey; James Lah; Ranjita Betarbet; Nicholas Seyfried; Allan Levey

2017

Subjects
  • Chemistry, Biochemistry
  • Health Sciences, Immunology
  • File Download
  • View Abstract

Abstract:Close

BACKGROUND: Kv1.3 potassium channels regulate microglial functions and are overexpressed in neuroinflammatory diseases. Kv1.3 blockade may selectively inhibit pro-inflammatory microglia in neurological diseases but the molecular and cellular mechanisms regulated by Kv1.3 channels are poorly defined. METHODS: We performed immunoblotting and flow cytometry to confirm Kv1.3 channel upregulation in lipopolysaccharide (LPS)-activated BV2 microglia and in brain mononuclear phagocytes freshly isolated from LPS-treated mice. Quantitative proteomics was performed on BV2 microglia treated with control, LPS, ShK-223 (highly selective Kv1.3 blocker), and LPS+ShK-223. Gene ontology (GO) analyses of Kv1.3-dependent LPS-regulated proteins were performed, and the most representative proteins and GO terms were validated. Effects of Kv1.3-blockade on LPS-activated BV2 microglia were studied in migration, focal adhesion formation, reactive oxygen species production, and phagocytosis assays. In vivo validation of protein changes and predicted molecular pathways were performed in a model of systemic LPS-induced neuroinflammation, employing antigen presentation and T cell proliferation assays. Informed by pathway analyses of proteomic data, additional mechanistic experiments were performed to identify early Kv1.3-dependent signaling and transcriptional events. RESULTS: LPS-upregulated cell surface Kv1.3 channels in BV2 microglia and in microglia and CNS-infiltrating macrophages isolated from LPS-treated mice. Of 144 proteins differentially regulated by LPS (of 3141 proteins), 21 proteins showed rectification by ShK-223. Enriched cellular processes included MHCI-mediated antigen presentation (TAP1, EHD1), cell motility, and focal adhesion formation. In vitro, ShK-223 decreased LPS-induced focal adhesion formation, reversed LPS-induced inhibition of migration, and inhibited LPS-induced upregulation of EHD1, a protein involved in MHCI trafficking. In vivo, intra-peritoneal ShK-223 inhibited LPS-induced MHCI expression by CD11b(+)CD45(low) microglia without affecting MHCI expression or trafficking of CD11b(+)CD45(high) macrophages. ShK-223 inhibited LPS-induced MHCI-restricted antigen presentation to ovalbumin-specific CD8(+) T cells both in vitro and in vivo. Kv1.3 co-localized with the LPS receptor complex and regulated LPS-induced early serine (S727) STAT1 phosphorylation. CONCLUSIONS: We have unraveled novel molecular and functional roles for Kv1.3 channels in pro-inflammatory microglial activation, including a Kv1.3 channel-regulated pathway that facilitates MHCI expression and MHCI-dependent antigen presentation by microglia to CD8(+) T cells. We also provide evidence for neuro-immunomodulation by systemically administered ShK peptides. Our results further strengthen the therapeutic candidacy of microglial Kv1.3 channels in neurologic diseases.

Article

Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial

by Charity G. Patterson; Elizabeth Joslin; Alexandra B. Gil; Wendy Spigle; Todd Nemet; Stewart Factor; Madeleine Hackney; Joe Nocera; MariadeLourdes Tansey

2022

Subjects
  • Biology, Neuroscience
  • Psychology, Cognitive
  • File Download
  • View Abstract

Abstract:Close

Background: To date, no medication has slowed the progression of Parkinson’s disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exercising at high intensity, in terms of slowing disease progression, beyond the well-documented benefit of endurance training on a treadmill for fitness, gait, and functional mobility. This study will determine the efficacy of high-intensity endurance exercise as first-line therapy for persons diagnosed with PD within 3 years, and untreated with symptomatic therapy at baseline. Methods: This is a multicenter, randomized, evaluator-blinded study of endurance exercise training. The exercise intervention will be delivered by treadmill at 2 doses over 18 months: moderate intensity (4 days/week for 30 min per session at 60–65% maximum heart rate) and high intensity (4 days/week for 30 min per session at 80–85% maximum heart rate). We will randomize 370 participants and follow them at multiple time points for 24 months. The primary outcome is the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score (Part III) with the primary analysis assessing the change in MDS-UPDRS motor score (Part III) over 12 months, or until initiation of symptomatic antiparkinsonian treatment if before 12 months. Secondary outcomes are striatal dopamine transporter binding, 6-min walk distance, number of daily steps, cognitive function, physical fitness, quality of life, time to initiate dopaminergic medication, circulating levels of C-reactive protein (CRP), and brain-derived neurotrophic factor (BDNF). Tertiary outcomes are walking stride length and turning velocity. Discussion: SPARX3 is a Phase 3 clinical trial designed to determine the efficacy of high-intensity, endurance treadmill exercise to slow the progression of PD as measured by the MDS-UPDRS motor score. Establishing whether high-intensity endurance treadmill exercise can slow the progression of PD would mark a significant breakthrough in treating PD. It would have a meaningful impact on the quality of life of people with PD, their caregivers and public health. Trial registration: ClinicalTrials.govNCT04284436. Registered on February 25, 2020.

Article

Prolongation of evoked and spontaneous synaptic currents at the neuromuscular junction after activity blockade is caused by the upregulation of fetal acetylcholine receptors

by Xueyong Wang; Kathrin L. Engisch; Russell W. Teichert; Baldomero M. Olivera; Martin Pinter; Mark M. Rich

2006

Subjects
  • Biology, Neuroscience
  • Biology, Animal Physiology
  • File Download
  • View Abstract

Abstract:Close

It has been shown previously in a number of systems that after an extended block of activity, synaptic strength is increased. We found that an extended block of synaptic activity at the mouse neuromuscular junction, using a tetrodotoxin cuff in vivo, increased synaptic strength by prolonging the evoked endplate current (EPC) decay. Prolongation of EPC decay was accompanied by only modest prolongation of spontaneous miniature EPC (MEPC) decay. Prolongation of EPC decay was reversed when quantal content was lowered by reducing extracellular calcium. These findings suggested that the cause of EPC prolongation was presynaptic in origin. However, when we acutely inhibited fetal-type acetylcholine receptors (AChRs) using a novel peptide toxin (αA-conotoxin OIVA[K15N]), prolongation of both EPC and MEPC decay were reversed. We also blocked synaptic activity in a mutant strain of mice in which persistent muscle activity prevents upregulation of fetal-type AChRs. In these mice, there was no prolongation of EPC decay. We conclude that upregulation of fetal-type AChRs after blocking synaptic activity causes modest prolongation of MEPC decay that is accompanied by much greater prolongation of EPC decay. This might occur if acetylcholine escapes from endplates and binds to extrajunctional fetal-type AChRs only during large, evoked EPCs. Our study is the first to demonstrate a functional role for upregulation of extrajunctional AChRs.

Article

RNA-Seq analysis of glycosylation related gene expression in Streptozotocin-induced diabetic rat kidney inner medulla

by Xiaoqian Qian; Xuechen Li; Titilayo Ilori; Janet Klein; Rebecca P. Hughey; Cong-jun Li; Abdel A. Alli; Zhengyu Guo; Peng Yu; Xiang Song; Guangping Chen

2013

Subjects
  • Biology, Cell
  • Health Sciences, Medicine and Surgery
  • Computer Science
  • File Download
  • View Abstract

Abstract:Close

The UT-A1 urea transporter is crucial to the kidney's ability to generate concentrated urine. Native UT-A1 from kidney inner medulla (IM) is a heavily glycosylated protein with two glycosylation forms of 97 and 117 kDa. In diabetes, UT-A1 protein abundance, particularly the 117 kD isoform, is significantly increased corresponding to an increased urea permeability in perfused IM collecting ducts, which plays an important role in preventing the osmotic diuresis caused by glucosuria. However, how the glycan carbohydrate structure change and the glycan related enzymes regulate kidney urea transport activity, particularly under diabetic condition, is largely unknown. In this study, using sugar-specific binding lectins, we found that the carbohydrate structure of UT-A1 is changed with increased amounts of sialic acid, fucose, and increased glycan branching under diabetic conditions. These changes were accompanied by altered UT-A1 association with the galectin proteins, β-galactoside glycan binding proteins. To explore the molecular basis of the alterations of glycan structures, the highly sensitive next generation sequencing (NGS) technology, Illumina RNA-seq, was employed to analyze genes involved in the process of UT-A1 glycosylation using streptozotocin (STZ)—induced diabetic rat kidney. Differential gene expression analysis combining with quantitative PCR revealed that expression of a number of important glycosylation related genes were changed under diabetic conditions. These genes include the glycosyltransferase genes Mgat4a, the sialylation enzymes St3gal1 and St3gal4 and glycan binding protein galectin-3, -5, -8, and -9. In contrast, although highly expressed in kidney IM, the glycosyltransferase genes Mgat1, Mgat2, and fucosyltransferase Fut8, did not show any changes. Conclusions: In diabetes, not only is UT-A1 protein abundance increased but the protein's glycan structure is also significantly changed. UT-A1 protein becomes highly sialylated, fucosylated and branched. Consistently, a number of crucial glycosylation related genes are changed under diabetic conditions. The alteration of these genes may contribute to changes in the UT-A1 glycan structure and therefore modulate kidney urea transport activity and alleviate osmotic diuresis caused by glucosuria in diabetes.

Article

Rat motoneuron properties recover following reinnervation in the absence of muscle activity and evoked acetylcholine release

by Edyta K. Bichler; Dario Carrasco; Mark M Rich; Timothy C Cope; Martin Pinter

2007

Subjects
  • Biology, Physiology
  • Biology, Neuroscience
  • View on PubMed Central
  • View Abstract

Abstract:Close

Available evidence supports the idea that muscle fibres provide retrograde signals that enable the expression of adult motoneuron electrical properties but the mechanisms remain unknown. We showed recently that when acetylcholine receptors are blocked at motor endplates, the electrical properties of rat motoneurons change in a way that resembles changes observed after axotomy. This observation suggests that receptor blockade and axotomy interrupt the same signalling mechanisms but leaves open the possibility that the loss of muscle fibre activity underlies the observed effects. To address this issue, we examined the electrical properties of axotomized motoneurons following reinnervation. Ordinarily, these properties return to normal following reinnervation and re-activation of muscle, but in this study muscle fibre activity and evoked acetylcholine release were prevented during reinnervation by blocking axonal conduction. Under these conditions, the properties of motoneurons that successfully reinnervated muscle fibres recovered to normal despite the absence of muscle fibre activity and evoked release. We conclude that the expression of motoneuron electrical properties is not regulated by muscle fibre activity but rather by a retrograde signalling system coupled to activation of endplate acetylcholine receptors. Our results indicate that spontaneous release of acetylcholine from regenerated motor terminals is sufficient to operate the system.

Article

Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis

by Orion Keifer; Juanmarco Gutierrez; Mark T. Butt; Sarah D. Cramer; Raymond Bartus; MariadeLourdes Tansey; Daniel Deaver; Alexandre Betourne; Nicholas Boulis

2023

Subjects
  • Biology, Neuroscience
  • Chemistry, Pharmaceutical
  • File Download
  • View Abstract

Abstract:Close

Riluzole is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis (ALS). However, oral riluzole efficacy is modest at best, further it is known to have large inter-individual variability of serum concentration and clearance, is formulated as an oral drug in a patient population plagued with dysphagia, and has known systemic sideeffects like asthenia (limiting patient compliance) and elevated liver enzymes. In this context, we postulated that continuous intrathecal (IT) infusion of low doses of riluzole could provide consistent elevations of the drug spinal cord (SC) concentrations at or above those achieved with oral dosing, without increasing the risk for adverse events associated with systemic drug exposure or off-target side effects in the brain. We developed a formulation of riluzole for IT delivery and conducted our studies in purpose-bred hound dogs. Our non- GLP studies revealed that IT infusion alone was able to increase SC concentrations above those provided by oral administration, without increasing plasma concentrations. We then conducted two GLP studies that combined IT infusion with oral administration at human equivalent dose, to evaluate SC and brain concentrations of riluzole along with assessments of safety and tolerability. In the 6-week study, the highest IT dose (0.2 mg/hr) was well tolerated by the animals and increased SC concentrations above those achieved with oral riluzole alone, without increasing brain concentrations. In the 6-month study, the highest dose tested (0.4 mg/hr) was not tolerated and yielded SC significantly above those achieved in all previous studies. Our data show the feasibility and safety profile of continuous IT riluzole delivery to the spinal cord, without concurrent elevated liver enzymes, and minimal brain concentrations creating another potential therapeutic route of delivery to be used in isolation or in combination with other therapeutics."

Article

Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: implications for disease-dependent drug–drug interactions

by Beatrice A Nyagode; Roya Jahangardi; Matthew D Merrell; MariadeLourdes Tansey; Edward T Morgan

2014

Subjects
  • Health Sciences, Pharmacology
  • Biology, Physiology
  • File Download
  • View Abstract

Abstract:Close

We studied the impact of administering XPro1595, a novel antagonist of soluble tumor necrosis factor-α (TNFα), on the regulation of hepatic cytochrome P450 enzymes in the C. rodentium model of infectious colitis. XPro1595 was administered subcutaneously every three days throughout the infection, or as a single injection near the peak of infection. When given throughout the infection, XPro1595 selectively blocked the down-regulation of Cyp3a11 and 3a25 mRNAs, as well as the induction of Cyp2a4/5, without affecting the down-regulation of Cyp4a10, Cyp4a14, Cyp2b10 or flavin-mooxygenase-3. Induction of Cyp3a11, Cyp3a25, Cyp2c29 and Cyp3a13 mRNAs were observed only in XPro1595-treated mice. Administration of a single dose of XPro1595 was relatively ineffective. These results a) confirm the role of soluble TNFα in hepatic Cyp3a regulation during infectious colitis deduced from studies in TNFα receptor-1 knockout mice; b) indicate the potential for soluble TNFα-specific antagonists to cause disease-dependent drug-drug interactions; and, c) suggest a novel mechanism by which an anti-inflammatory therapeutic protein can produce an opposite effect to that of the disease by selectively neutralizing one of multiple signals regulating drug-metabolizing enzyme expression. More research is needed to determine whether or not this is applicable to other diseases or disease models.
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. ...
>
Site Statistics
  • 35,724
  • Total Works
  • 9,167,716
  • Downloads
  • 245,590
  • Downloads This Year

Copyright © 2016 Emory University - All Rights Reserved
540 Asbury Circle, Atlanta, GA 30322-2870
(404) 727-6861
Privacy Policy | Terms & Conditions

v2.2.8-dev

Contact Us
Download now